Formatech, Inc. Donates Services to Formulate and Fill TRACON Pharmaceuticals, Inc.'s TRC102 Compound under Its “Fillanthropy(TM) Program”

ANDOVER, Mass.--(BUSINESS WIRE)--Today, Formatech, Inc. announces the selection of Tracon Pharmaceuticals’ TRC102 clinical product as the next Fillanthropy™ Program candidate. Under this program, Formatech donates the services required to aseptically fill and finish one lot of the drug candidate to support Tracon’s upcoming clinical trials.

MORE ON THIS TOPIC